273 related articles for article (PubMed ID: 30368666)
1. Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate.
Kordiak J; Szemraj J; Grabska-Kobylecka I; Bialasiewicz P; Braun M; Kordek R; Nowak D
J Cancer Res Clin Oncol; 2019 Jan; 145(1):241-251. PubMed ID: 30368666
[TBL] [Abstract][Full Text] [Related]
2. Complete surgical resection of lung tumor decreases exhalation of mutated KRAS oncogene.
Kordiak J; Szemraj J; Hamara K; Bialasiewicz P; Nowak D
Respir Med; 2012 Sep; 106(9):1293-300. PubMed ID: 22795503
[TBL] [Abstract][Full Text] [Related]
3. Detection of p53 gene mutations in exhaled breath condensate of non-small cell lung cancer patients.
Gessner C; Kuhn H; Toepfer K; Hammerschmidt S; Schauer J; Wirtz H
Lung Cancer; 2004 Feb; 43(2):215-22. PubMed ID: 14739043
[TBL] [Abstract][Full Text] [Related]
4. Concordance in molecular genetic analysis of tumour tissue, plasma, and exhaled breath condensate samples from lung cancer patients.
Tetik Vardarli A; Pelit L; Aldag C; Korba K; Celebi C; Dizdas TN; Uzun UC; Tayfur E; Aykut A; Karakus HS; Baysal E; Goksel O; Pelit F; Yalcin F; Ertas FN; Basbinar Y; Veral A; Gunduz C; Goksel T
J Breath Res; 2020 Apr; 14(3):036001. PubMed ID: 32031993
[TBL] [Abstract][Full Text] [Related]
5. Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Youssef O; Knuuttila A; Piirilä P; Böhling T; Sarhadi V; Knuutila S
Anticancer Res; 2018 Oct; 38(10):5627-5634. PubMed ID: 30275180
[TBL] [Abstract][Full Text] [Related]
6. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing.
Zhang Y; Chang L; Yang Y; Fang W; Guan Y; Wu A; Hong S; Zhou H; Chen G; Chen X; Zhao S; Zheng Q; Pan H; Zhang L; Long H; Yang H; Wang X; Wen Z; Wang J; Yang H; Xia X; Zhao Y; Hou X; Ma Y; Zhou T; Zhang Z; Zhan J; Huang Y; Zhao H; Zhou N; Yi X; Zhang L
Mol Cancer; 2019 Jan; 18(1):7. PubMed ID: 30626401
[TBL] [Abstract][Full Text] [Related]
7. Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma.
Guibert N; Pradines A; Farella M; Casanova A; Gouin S; Keller L; Favre G; Mazieres J
Lung Cancer; 2016 Oct; 100():1-4. PubMed ID: 27597273
[TBL] [Abstract][Full Text] [Related]
8. Exhaled breath condensate efficacy to identify mutations in patients with lung cancer: A pilot study.
Kazeminasab S; Ghanbari R; Emamalizadeh B; Jouyban-Gharamaleki V; Taghizadieh A; Jouyban A; Khoubnasabjafari M
Nucleosides Nucleotides Nucleic Acids; 2022; 41(4):370-383. PubMed ID: 35249462
[TBL] [Abstract][Full Text] [Related]
9. Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.
Das BR; Bhaumik S; Ahmad F; Mandsaurwala A; Satam H
Pathol Oncol Res; 2015 Jul; 21(3):675-87. PubMed ID: 25637496
[TBL] [Abstract][Full Text] [Related]
10. K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma.
Li S; Rosell R; Urban A; Font A; Ariza A; Armengol P; Abad A; Navas JJ; Monzo M
Lung Cancer; 1994 Jul; 11(1-2):19-27. PubMed ID: 8081702
[TBL] [Abstract][Full Text] [Related]
11. Loss of heterozygosity of chromosome 12p does not correlate with KRAS mutation in non-small cell lung cancer.
Uchiyama M; Usami N; Kondo M; Mori S; Ito M; Ito G; Yoshioka H; Imaizumi M; Ueda Y; Takahashi M; Minna JD; Shimokata K; Sekido Y
Int J Cancer; 2003 Dec; 107(6):962-9. PubMed ID: 14601056
[TBL] [Abstract][Full Text] [Related]
12. Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients.
Fathi Z; Mousavi SAJ; Roudi R; Ghazi F
PLoS One; 2018; 13(7):e0200633. PubMed ID: 30048458
[TBL] [Abstract][Full Text] [Related]
13. Exhaled Breath Condensate (EBC) analysis of circulating tumour DNA (ctDNA) using a lung cancer specific UltraSEEK oncogene panel.
Ryan DJ; Toomey S; Smyth R; Madden SF; Workman J; Cummins R; Sheehan K; Fay J; Naidoo J; Breathnach OS; Morris PG; Grogan L; O'Brien ME; Sulaiman I; Hennessy BT; Morgan RK
Lung Cancer; 2022 Jun; 168():67-73. PubMed ID: 35526313
[TBL] [Abstract][Full Text] [Related]
14. KRAS codon 12 mutations in Australian non-small cell lung cancer.
Fong KM; Zimmerman PV; Smith PJ
Aust N Z J Med; 1998 Apr; 28(2):184-9. PubMed ID: 9612526
[TBL] [Abstract][Full Text] [Related]
15. Gene mutation analysis in non-small cell lung cancer patients using bronchoalveolar lavage fluid and tumor tissue as diagnostic markers.
Li J; Hu YM; Wang Y; Tang XP; Shi WL; Du YJ
Int J Biol Markers; 2014 Dec; 29(4):e328-36. PubMed ID: 24519547
[TBL] [Abstract][Full Text] [Related]
16. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
[TBL] [Abstract][Full Text] [Related]
17. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma.
Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M
J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial DNA mutations in exhaled breath condensate of patients with lung cancer.
Yang Ai SS; Hsu K; Herbert C; Cheng Z; Hunt J; Lewis CR; Thomas PS
Respir Med; 2013 Jun; 107(6):911-8. PubMed ID: 23507584
[TBL] [Abstract][Full Text] [Related]
19. Presence of cancer-associated mutations in exhaled breath condensates of healthy individuals by next generation sequencing.
Youssef O; Knuuttila A; Piirilä P; Böhling T; Sarhadi V; Knuutila S
Oncotarget; 2017 Mar; 8(11):18166-18176. PubMed ID: 28199989
[TBL] [Abstract][Full Text] [Related]
20. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
